Advanced Materials · 2022 · 128 citations · 76 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCancer NanomedicineCheckpoint Inhibitor TherapyNanomedicineNanoparticle DesignProtein-based NanomaterialsAntitumor Immune ActivationCancer Immunotherapy NanoparticlesImmunogenic Cell Death InductionNanoparticle-based ImmunotherapyPolymer NanoparticlesProgrammed Cell Death Ligand 1 InhibitionProgrammed Cell Death Ligand 1 RegulationProgrammed Death-ligand 1 Signaling
Immunotherapy has received tremendous attention for tumor treatment, but the efficacy is greatly hindered by insufficient tumor-infiltration of immune cells and immunosuppressive tumor microenvironment. The strategy that can efficiently activate cytotoxic T lymphocytes and inhibit negative immune regulators will greatly amplify immunotherapy outcome, which is however very rare. Herein, a new kind of semiconducting polymer (SP) nanoparticles is developed, featured with surface-mimicking protein secondary structure (SPSS NPs) for self-synergistic cancer immunotherapy by combining immunogenic cell death (ICD) and immune checkpoint blockade therapy. The SPs with excellent photodynamic property are synthesized by rational fluorination, which can massively induce ICD. Additionally, the peptide antagonists are introduced and self-assembled into β-sheet protein secondary structures on the photodynamic NP surface via preparation process optimization, which function as efficient lysosome-targeting chimaeras (LYTACs) to mediate the degradation of programmed cell death ligand-1 (PD-L1) in lysosome. In vivo experiments demonstrate that SPSS NPs can not only elicit strong antitumor immunity to suppress both primary tumor and distant tumor, but also evoke long-term immunological memory against tumor rechallenge. This work introduces a new kind of robust immunotherapy agents by combining well-designed photosensitizer-based ICD induction and protein secondary structures-mediated LYTAC-like multivalence PD-L1 blockade, rendering great promise for synergistic immunotherapy.
76
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations
Medicine, Immunology, Oncology +17
Selective Differentiation of Neural Progenitor Cells by High-Epitope Density Nanofibers
Gabriel A. Silva, Catherine Czeisler, Krista L. Niece et al. · Science · 2004 · 2.2K citations
Immunogenic death of colon cancer cells treated with oxaliplatin
Antoine Tesnière, F. Schlemmer, Valérie Boige et al. · Oncogene · 2009 · 1.1K citations
Medicine, Oncology, Pharmacology +14
Lysosome-targeting chimaeras for degradation of extracellular proteins
Steven M. Banik, Kayvon Pedram, Simon Wisnovsky et al. · Nature · 2020 · 1.1K citations · Full text